References
- Hay RJ. Tropical fungal infections. Pharm Int 1985;6:97–101
- Zhang AY, Camp WL, Elewski BE. Advances in topical and systemic antifungals. Dermatol Clin 2007;25:165–183
- Schwartz RA. Superficial fungal infections. Lancet 2004;364:1173–1182
- Oliveira PC, Medeiros CSQ, Macedo DPC, et al. Ciclopirox olamine: an antifungal alternative against Cryptococcosis. Lett Appl Microbiol 2010;51:485–489
- Cullen SI, Frost P, Jacobson C, et al. Treatment of Tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. Clin Ther 1985;7:574–583
- Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008;166:353–367
- Abrams BB, Hanel H, Hoehler T. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin Dermatol 1991;9:471–477
- Kovacs SO, Hruza LL. Superficial fungal infections. Postgrad Med 1995;98:61–75
- Weir SJ, Patton L, Castle K, et al. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy. J Clin Pharm Ther 2011;36:128–134
- Mendez-Tovar LJ. Pathogenesis of dermatophytosis and tinea versicolor. Clin Dermatol 2010;28:185–189
- Hänel H, Raether W, Dittmar W. Evaluation of fungicidal action in vitro and in a skin model, considering the influence of penetration kinetics of various standard antimycotics. Ann N Y Acad Sci 1988;544:329–337
- Aly R, Maibach HI, Bagatell FK, et al. Ciclopirox olamine lotion 1%: bioequivalence to ciclopirox olamine cream 1% and clinical efficacy in Tinea Pedis. Clin Ther 1989;11:290–303
- Shah JC, Sadhale Y, Chilukuri DM. Cubic phase gels as drug delivery systems. Adv Drug Deliv Rev 2001;47:229–250
- Valenta C, Janish M. Permeation of cyproterone acetate through pig skin from different vehicles with phospholipids. Int J Pharm 2003;258:133–139
- Loftsson T, Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001;225:15–30
- Masson M, Loftsson T, Masson G, Stefansson E. Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing. J Control Release 1999;59:107–118
- Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603–606
- Billich A, Aschauer H, Aszódi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and Tacrolimus. Int J Pharm 2004;269:29–35
- ICH Expert Working Group. ICH harmonized Tripartite Guideline. International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use. Validation of Analytical Procedures: Methodology (ICH-Q2B), November, 1996
- Gonzalez AG, Herrador MA. A practical guide to analytical method validation, including measurement uncertainty and accuracy profiles. Trends Anal Chem 2007;26:227–238
- Brounagh RL, Collier SW. In vitro methods for measuring skin permeation. In: Zatz JL, ed. Skin permeation: fundamentals and application. 3rd ed. Wheaton: Allured Publishing Corporation; 1993:93–111
- Olejnik A, Goscianska J, Nowak I. Active compounds release from semisolid dosage forms. J Pharm Sci 2012;101:4032–4045
- Ostrenga J, Steinmet C. Poulsen B. Significance of vehicle composition. I. Relationship between topical vehicle composition, skin penetrability, and clinical efficacy. J Pharm Sci 1971;60:1175–1179
- Lopes LB, Vandewall H, Li HT, et al. Topical delivery of lycopene using microemulsions: enhanced skin penetration and tissue antioxidant activity. J Pharm Sci 2010;99:1346–1357
- Palliyil B, Lebo DB, Patel PR. A preformulation strategy for the selection of penetration enhancers for a transungual formulation. AAPS PharmSciTech 2013;14:682–691
- Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2012;64:128–137
- Jue SG, Dawson GW, Brogden RN. Ciclopirox olamine 1% cream: a preliminary review of its antimicrobial activity and therapeutic use. Drugs 1985;29:330–341
- Gupta AK. Ciclopirox: an overview. Int J Dermatol 2001;40:305–310
- Brinkmann I, Müller-Goymann CC. An attempt to clarify the influence of glycerol, propylene glycol, isopropyl myristate and a combination of propylene glycol and isopropyl myristate on human stratum corneum. Pharmazie 2005;60:215–220